Document is current
Any future updates will be listed below
-
Authors
Atmowihardjo, Leila http://orcid.org/0000-0002-7452-1867
Schippers, Job R.
Bartelink, Imke H.
Bet, Pierre M.
van Rein, Nienke
Purdy, Keith
Cavalla, David
Comberiati, Valérie
McElroy, Andrew
Snape, Sue D.
Bogaard, Harm Jan
Heunks, Leo
Juffermans, Nicole
Schultz, Marcus
Tuinman, Pieter R.
Bos, Lieuwe D. J.
Aman, Jurjan
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (101005142)
- License Information
-
More Information
Article History
Received: 1 June 2021
Accepted: 27 January 2022
First Online: 16 February 2022
Declarations
:
: The trial received ethical approval from the medical ethics review committee of the Amsterdam UMC, location VUMC, on 22.01.2021. The file number is 2020.0752. We certify that this trial has received approval from the appropriate ethical committee as described above.Consent for publication {32}Since all patients are intubated at randomization the legal representative will be asked for permission. The patient will be asked for permission as quickly as possible.
: JA is the inventor of a patent (WO2012150857A1, 2011) covering protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase Abl-related gene (Arg). JA has served as a non-compensated scientific advisor for Exvastat<sup>TM</sup>. All other authors have no competing interests.
